Rankings
▼
Calendar
KNSA Q4 2020 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena
KNSA
Kiniksa Pharmaceuticals, Ltd.
$3B
Q4 2020 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$53M
Net Income
-$54M
EPS (Diluted)
$-0.79
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$41M
Free Cash Flow
-$41M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$349M
Total Liabilities
$38M
Stockholders' Equity
$312M
Cash & Equivalents
$114M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
$0
—
Operating Income
-$53M
-$33M
-62.4%
Net Income
-$54M
-$32M
-68.7%
← FY 2020
All Quarters
Q1 2021 →